Good article. This milestone underscores ORI Capital's drive in meeting their ROI objectives and they did it in a brief 5 years since 2016.

They also achieved this healthy return by exciting Kymab whose drug KY1005 is only at the phase 1 and 2 stage of clinical trials. It would seem this is significantly behind in it's clinical development vs apabetalone which has achieved FDA breakthrough designation.

This suggests to me that ORI is not about to suffer fools for too long.

Like Buckeyes I have mixed feelings about Hepalink and ORI. There are many options that could occur. I just hope that one of the options will benefit retail shareholders like me. It can't get much worse than the current situation.

From my perspective I would like to see a reputable investor, possibly a well known BP, pitch in and acquire a very significant share position and play a strong role in BoM3. This would bring balance, get rid of the IP threat and possibly bring some competence to management.

I'm hoping the Covid trial will be a success but I'm in for the long run based on the peer reviewed science re apabetalone.

GLTA

Toinv